Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology
Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC points

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).


CME/CE Accreditation Information

Itinerary

Part 1

Optimizing Treatment for Patients with CLL - Baseline Assessment

The following questions are designed to assess your knowledge and practice of patients with relapsed/refractory CLL/SLL.

Module 1 - Overview of CLL/SLL Treatment Considerations

This module focuses on providing a comprehensive overview of the current treatment landscape for CLL, highlighting key considerations, and treatment options.

Module 2 - Current and Emerging Evidence for Targeted Therapies in CLL/SLL

This module focuses on the evidence underlying recently approved and emerging treatments for CLL, both in the front-line and in relapsed/refractory (R/R) settings.

Module 3 - Treatment Sequencing Considerations in CLL/SLL

This module focuses on diving deeply into the considerations for treatment sequencing after a patient has become intolerant to treatment or has disease progression.

Optimizing Treatment for Patients with CLL - Final Assessment

The following questions are designed to assess your gained knowledge and practice of patients with relapsed/refractory CLL/SLL.

Live Group Discussion 1

During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).

Part 2

Patient Case 1 – A 72-year-old male with a history of stage 3 CKD

72yo male with stage 3 CKD & CLL, 13q deletion & mutated IGHV, progresses from watchful waiting to requiring treatment (acalabrutinib). Considerations for new treatment after an adverse event (atrial fibrillation).

Patient Case 2 – A 66-year-old female with CLL

66-yr-old with CLL seeks new treatment after disease progression & BTK resistance. Group to explore subsequent line therapy options and selection considerations after disease progression.

Your action plan - chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and relapsed/refractory (R/R) CLL/SLL

Please share an action plan that you will implement to improve the diagnosis and management for your patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), or relapsed/refractory (R/R) CLL/SLL.

Live Group Discussion 2

During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.

Interested in becoming a Group Leader?

Requirements:
Experts in the management of patients with chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL). Apply Now

Interested in participating in this curriculum? You can join one of the following groups:

Cole Sterling, MD
Assistant Professor of Oncology
Lisa Nodzon, PhD, APRN, AOCNP
Lead Advanced Practice Professional